Allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes

Clinical Lymphoma, Myeloma and Leukemia

Volumn 13, Issue SUPPL. 2, 2013, Pages

  Oran, Betul ^a   Popat, Uday ^a   Andersson, Borje ^a   Champlin, Richard ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Allogeneic stem cell transplantation; Cytogenetics; Donor; Hypomethylating agents; MDS

Indexed keywords

AZACITIDINE; BUSULFAN; CYCLOPHOSPHAMIDE; FLUDARABINE; LENALIDOMIDE; MYCOPHENOLIC ACID; TACROLIMUS; TREOSULFAN;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER REGRESSION; COMORBIDITY; CONSERVATIVE TREATMENT; DISEASE COURSE; DISEASE FREE SURVIVAL; DONOR SELECTION; GRAFT VERSUS HOST REACTION; GROUPS BY AGE; HUMAN; LIFE EXPECTANCY; MAINTENANCE THERAPY; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; OUTCOME ASSESSMENT; OVERALL SURVIVAL; REDUCED INTENSITY CONDITIONING; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE;

ALLOGENEIC STEM CELL TRANSPLANTATION; CYTOGENETICS; DONOR; HYPOMETHYLATING AGENTS; MDS;

CYTOGENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MYELODYSPLASTIC SYNDROMES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 84889021001     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2013.07.012     Document Type: Review

References (49)

1. W.K. Hofmann, and H.P. Koeffler Myelodysplastic syndrome Annu Rev Med 56 2005 1 16
2. F.R. Appelbaum, S. Dahlberg, and E.D. Thomas Bone marrow transplantation or chemotherapy after remission induction for adults with acute nonlymphoblastic leukemia. A prospective comparison Ann Intern Med 101 1984 581 588
3. F.R. Appelbaum, R. Storb, and R.E. Ramberg Treatment of preleukemic syndromes with marrow transplantation Blood 69 1987 92 96
4. J. Sierra, W.S. Perez, and C. Rozman Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia Blood 100 2002 1997 2004
5. H. Castro-Malaspina, R.E. Harris, and J. Gajewski Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program Blood 99 2002 1943 1951
6. T. de Witte, F. Pikkemaat, and J. Hermans Genotypically nonidentical related donors for transplantation of patients with myelodysplastic syndromes: comparison with unrelated donor transplantation and autologous stem cell transplantation Leukemia 15 2001 1878 1884
7. M. Oosterveld, S. Suciu, and G. Verhoef The presence of an HLA-identical sibling donor has no impact on outcome of patients with high-risk MDS or secondary AML (sAML) treated with intensive chemotherapy followed by transplantation: results of a prospective study of the EORTC, EBMT, SAKK and GIMEMA Leukemia Groups (EORTC study 06921) Leukemia 17 2003 859 868
8. H.J. Deeg, H.M. Shulman, and J.E. Anderson Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age Blood 95 2000 1188 1194
9. P. Greenberg, C. Cox, and M.M. LeBeau International scoring system for evaluating prognosis in myelodysplastic syndromes Blood 89 1997 2079 2088
10. P.L. Greenberg, H. Tuechler, and J. Schanz Revised international prognostic scoring system for myelodysplastic syndromes Blood 120 2012 2454 2465
11. J. Schanz, H. Tuchler, and F. Sole New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge J Clin Oncol 30 2012 820 829
12. H. Kantarjian, S. O'Brien, and F. Ravandi Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System Cancer 113 2008 1351 1361
13. L. Malcovati, M.G. Porta, and C. Pascutto Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making J Clin Oncol 23 2005 7594 7603
14. F.R. Appelbaum, and J. Anderson Allogeneic bone marrow transplantation for myelodysplastic syndrome: outcomes analysis according to IPSS score Leukemia 12 1998 S25 S29
15. E.P. Alessandrino, M.G. Della Porta, and A. Bacigalupo WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO) Blood 112 2008 895 902
16. H.J. Deeg, B. Storer, and J.T. Slattery Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome Blood 100 2002 1201 1207
17. T. de Witte, R. Brand, and A. van Biezen Allogeneic stem cell transplantation for patients with refractory anaemia with matched related and unrelated donors: delay of the transplant is associated with inferior survival Br J Haematol 146 2009 627 636
18. C.S. Cutler, S.J. Lee, and P. Greenberg A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome Blood 104 2004 579 585
19. M.C. Ethier, M. Science, and J. Beyene Mould-active compared with fluconazole prophylaxis to prevent invasive fungal diseases in cancer patients receiving chemotherapy or haematopoietic stem-cell transplantation: a systematic review and meta-analysis of randomised controlled trials Br J Cancer 106 2012 1626 1637
20. G.L. de Oliveira, K.C. Malmegrim, and A.F. Ferreira Up-regulation of fas and fasL pro-apoptotic genes expression in type 1 diabetes patients after autologous haematopoietic stem cell transplantation Clin Exp Immunol 168 2012 291 302
21. E. Jabbour, G. Garcia-Manero, and N. Batty Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy Cancer 116 2010 3830 3834
22. T. Prebet, S.D. Gore, and B. Esterni Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure J Clin Oncol 29 2011 3322 3327
23. G. Metan, A.N. Koc, and L.G. Kaynar What is the role of the (1 - >3)-beta-d-glucan assay in the screening of patients undergoing autologous haematopoietic stem-cell transplantation? Mycoses 56 2013 34 38
24. M.R. Litzow, S. Tarima, and W.S. Perez Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia Blood 115 2009 1850 1857
25. Z. Lim, R. Brand, and R. Martino Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia J Clin Oncol 28 2010 405 411
26. B.L. McClune, D.J. Weisdorf, and T.L. Pedersen Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome J Clin Oncol 28 2010 1878 1887
27. M.L. Sorror, B.M. Sandmaier, and B.E. Storer Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation J Clin Oncol 25 2007 4246 4254
28. Z.Y. Lim, W. Ingram, and R. Brand Impact of pretransplant comorbidities on alemtuzumab-based reduced-intensity conditioning allogeneic hematopoietic SCT for patients with high-risk myelodysplastic syndrome and AML Bone Marrow Transplant 45 2010 633 639
29. P. Armand, H.T. Kim, and C.S. Cutler Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation Blood 109 2007 4586 4588
30. U. Platzbecker, M. Bornhauser, and U. Germing Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS) Biol Blood Marrow Transplant 14 2008 1217 1225
31. E.P. Alessandrino, M.G. Della Porta, and A. Bacigalupo Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study Haematologica 95 2010 476 484
32. P. Armand, H.T. Kim, and J. Rhodes Iron overload in patients with acute leukemia or MDS undergoing myeloablative stem cell transplantation Biol Blood Marrow Transplant 17 2011 852 860
33. J.W. Lee, H.J. Kang, and E.K. Kim Effect of iron overload and iron-chelating therapy on allogeneic hematopoietic SCT in children Bone Marrow Transplant 44 2009 793 797
34. R. Martino, S. Iacobelli, and R. Brand Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes Blood 108 2006 836 846
35. S.M. Luger, O. Ringden, and M.J. Zhang Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS Bone Marrow Transplant 47 2012 203 211
36. B.S. Andersson, A. Kashyap, and V. Gian Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study Biol Blood Marrow Transplant 8 2002 145 154
37. G. Alatrash, M. de Lima, and N. Hamerschlak Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life Biol Blood Marrow Transplant 17 2011 1490 1496
38. N. Kroger, A. Shimoni, and T. Zabelina Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS) Bone Marrow Transplant 37 2006 339 344
39. T. Ruutu, L. Volin, and D.W. Beelen Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trial Haematologica 96 2011 1344 1350
40. C. Kollman, C.W. Howe, and C. Anasetti Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age Blood 98 2001 2043 2051
41. N. Kroger, T. Zabelina, and L. de Wreede Allogeneic stem cell transplantation for older advanced MDS patients: improved survival with young unrelated donor in comparison with HLA-identical siblings Leukemia 27 2013 604 609
42. E.D. Warlick, A. Cioc, and T. Defor Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden Biol Blood Marrow Transplant 15 2009 30 38
43. M. Robin, G.F. Sanz, and I. Ionescu Unrelated cord blood transplantation in adults with myelodysplasia or secondary acute myeloblastic leukemia: a survey on behalf of Eurocord and CLWP of EBMT Leukemia 25 2011 75 81
44. L. Luznik, P.V. O'Donnell, and H.J. Symons HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide Biol Blood Marrow Transplant 14 2008 641 650
45. H.J. Deeg, B.L. Scott, and M. Fang Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS Blood 120 2012 1398 1408
46. M. de Lima, S. Giralt, and P.F. Thall Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study Cancer 116 2010 5420 5431
47. L. Mollgard, L. Saft, and M.B. Treppendahl Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities Haematologica 96 2011 963 971
48. E. Kneppers, B. van der Holt, and M.J. Kersten Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial Blood 118 2011 2413 2419
49. U. Platzbecker, M. Wermke, and J. Radke Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial Leukemia 26 2012 381 389